T-DM1 shows across-board benefits as EMILIA breast cancer data unveiled
This article was originally published in Scrip
Executive Summary
Women treated with Genentech's antibody-drug conjugate T-DM1 (trastuzumab emtansine) lived nearly six months longer than HER2-positive advanced breast cancer patients treated with lapatinib plus capecitabine in the Phase III EMILIA study used to support applications for regulatory approval of the closely watched second-line therapy.